Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
F Scaldaferri
Observed names:
Franco SCALDAFERRI,
Franco Scaldaferri
Institutions:
Università Cattolica del Sacro Cuore,
Agostino Gemelli University Polyclinic,
Istituti di Ricovero e Cura a Carattere Scientifico
Observed institutions:
Università Cattolica del Sacro Cuore,
Agostino Gemelli University Polyclinic,
Istituti di Ricovero e Cura a Carattere Scientifico
ORCID:
0000-0001-8334-7541
Observed ORCID:
0000-0001-8334-7541
OpenAlex ID:
A5123487581
P1014 Multicenter Real-World Outcomes of Risankizumab in Crohn’s Disease: The RESOLVE IG-IBD Study
2026
·
F Scaldaferri
, F Di Vincenzo
, et al.
·
Journal of Crohn s and Colitis
·
3
DOP082 Real-world effectiveness and safety of three JAK inhibitors for ulcerative colitis: an IPTW analysis from IN-IBD
2026
·
G Mocci
, A Pasta
, et al.
·
Journal of Crohn s and Colitis
·
1
GENZ-AF-IBD study design: a hybrid phase 4 clinical equivalence trial using AI-based synthetic control arms to compare generic apixaban with the originator in patients with atrial fibrillation
2026
·
M Narducci
, V Vassilikos
, et al.
·
European Heart Journal
PDF
Agricultural chemicals and gut microbiota dysbiosis: implications for the pathogenesis of inflammatory bowel disease
2026
·
Guia Becherucci
, Pierluigi Puca
, et al.
·
Frontiers in Nutrition
PDF
Capsule Endoscopy for Treat-to-Target Monitoring in Crohn’s Disease: A Systematic Review and Meta-Analysis
2026
·
C Marmo
, F S Puca
, et al.
·
Endoscopy
Restorative Surgery in Adult Short Bowel Syndrome: Outcomes from a Single-Center Experience with an Illustrative Complex Case
2026
·
Federica Galiandro
, Carmen Nesci
, et al.
·
Journal of Clinical Medicine
PDF
Modulation of IL33/ST2 axis and mucosal healing in IBD: state of the art and future perspectives
2026
·
Greta MIGLIORE
, Sara TROISI
, et al.
·
Minerva Gastroenterology
P0176 Exploring Microbiota-Immune Interactions in Short Bowel Syndrome and Crohn’s Disease in a model of human microbiota associated mice
2026
·
L Masi
, V Petito
, et al.
·
Journal of Crohn s and Colitis
P0133 Distinct CD8+ T-cell immune signatures in UC patients under different biologic therapies: evidence of selective modulation by IL-12/23 inhibition
2026
·
G Migliore
, G Rumi
, et al.
·
Journal of Crohn s and Colitis
P0093 Divergent Effects of Diet and Fecal Microbiota Transplantation on Regional Gut Inflammation in Humanized IBD Models
2026
·
S Deleu
, K Vidmar
, et al.
·
Journal of Crohn s and Colitis
P0222 Determinants of Sarcopenia in Crohn’s Disease: Effects of Short Bowel Syndrome and Protein Intake
2026
·
G Becherucci
, A Del Gaudio
, et al.
·
Journal of Crohn s and Colitis
PDF
P0839 Safety and effectiveness of thromboprophylaxis for venous thromboembolic events in hospitalised patients with IBD
2026
·
L Laterza
, N Di Giorgi
, et al.
·
Journal of Crohn s and Colitis
P1159 Pooled analysis of efficacy and safety of once-daily oral obefazimod in European patients from the ABTECT Phase 3, double-blind, placebo-controlled induction trials
2026
·
F Scaldaferri
, U Seidler
, et al.
·
Journal of Crohn s and Colitis
PDF
P0365 The Prognostic Impact of Sarcopenia on Surgical Outcomes and Postoperative Recurrence After Ileocolic Resection in Crohn’s Disease
2026
·
A Del Gaudio
, F Di Vincenzo
, et al.
·
Journal of Crohn s and Colitis
PDF
P1324 Integrated multiomic profiling reveals distinct signatures in Short Bowel Syndrome and Crohn’s Disease patients at variable risk for Intestinal Failure
2026
·
L R Lopetuso
, V Petito
, et al.
·
Journal of Crohn s and Colitis
PDF
DOP035 Upadacitinib: Personalized Goals for Remission and Disease Evaluation in Patients with Crohn’s Disease (UPGRADE-CD) - A Multicenter Prospective Study from the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD).
2026
·
B Barberio
, F Scaldaferri
, et al.
·
Journal of Crohn s and Colitis
P0443 Long-term outcome of patients with Ulcerative Colitis after Ileal Pouch–Anal Anastomosis: the Latium NET study, preliminary data
2026
·
G Cuccia
, A Aratari
, et al.
·
Journal of Crohn s and Colitis
P0379 Group-Based Acceptance and Commitment Therapy in Inflammatory Bowel Disease: Clinical Effectiveness in Real-World Practice
2026
·
G Spagnolo
, D Ferrarese
, et al.
·
Journal of Crohn s and Colitis
P0146 Mediterranean Diet Improves Disease Activity and Microbial Diversity, While Donor-Dependent FMT Independently Reduces Disease Activity in Humanized UC Mice
2026
·
S Deleu
, S Troisi
, et al.
·
Journal of Crohn s and Colitis
P0922 Impact of obefazimod treatment on histologic and combined histologic-endoscopic outcomes in patients with moderately to severely active ulcerative colitis: results from the ABTECT-1 and ABTECT-2 Phase 3, double-blind, placebo-controlled induction trials
2026
·
F Magro
, B E Sands
, et al.
·
Journal of Crohn s and Colitis
PDF
P1318 The IBD-associated L503F variant of Organic Cation Transporter Novel (OCTN-)1 predicts a better response to antiTNFalpha in patients with ulcerative colitis: a single center analysis.
2026
·
P Puca
, L Masi
, et al.
·
Journal of Crohn s and Colitis
P0127 Unravelling IL-33/ST2 Mucosal Patterns in Crohn’s Disease and Ulcerative Colitis
2026
·
C Pane
, M Di Mattia
, et al.
·
Journal of Crohn s and Colitis
P0961 An inverse propensity score-weighted comparison between Vedolizumab, Ustekinumab, and Tofacitinib in ulcerative colitis patients refractory or intolerant to anti-TNF therapies
2026
·
G Mocci
, E V Savarino
, et al.
·
Journal of Crohn s and Colitis
P1077 Impact of baseline body mass index (BMI) on efficacy of obefazimod in patients with moderately to severely active ulcerative colitis: results from the Phase 3 ABTECT induction trials
2026
·
D T Rubin
, M C Dubinsky
, et al.
·
Journal of Crohn s and Colitis
P1015 Effectiveness and safety of mirikizumab in ulcerative colitis: real-world data from the Latium net
2026
·
M Murgiano
, P Balestrieri
, et al.
·
Journal of Crohn s and Colitis
PDF
Show more works
View as search
Works count:
26
Citation count:
4
H-index:
1
I10-index:
Year
Topic
Type